Enrolling
Fecal microbiota transplantation to reduce immune activation in ART-treated people living with HIV with low CD4/CD8 ratio
Learn MoreCompleted
Exploring the role of the soluble glycoprotein 120 as a pan-toxin driving immune dysfunction and accelerated aging in people living with HIV
Learn MoreOngoing
Interplay between expanded endocannabinoid (eCB) system and inflamm-aging: Implication for accelerated atherosclerosis in people living with HIV (PLWH) under ART
Learn MoreOngoing
Influence of a 3-month letermovir treatment on gut inflammation in ART-treated HIV-infected persons in an open labelled controlled randomized study
Learn MoreReporting
Vaccines in a Time of Dual Pandemic: COVID-19 Vaccine in People with HIV
Learn MoreOngoing
Preventing HIV by targeting the immune system instead of the virus
Learn MoreReporting
A proof-of-concept study to assess the effect of recombinant human growth hormone on the size of the replication-competent viral reservoir in HIV-infected individuals on suppressive ART
Learn MoreReporting
Predictive value of inflammatory biomarkers in untreated HIV disease progression, and their response to initiation of antiretroviral therapy
Learn MoreReporting
A study of host and viral factors associated with disease progression in long term HIV infected subjects
Learn More
CTN Trials have been approved by the Community Advisory Committee of the Canadian HIV Trials Network and the Network’s Scientific Review Committee, or other national peer-review panels such as those at the Canadian Institutes of Health Research and the U.S. National Institutes of Health. CTNPT studies are small-scale investigations designed to determine the feasibility of research concepts, and do not all go through the regular CTN clinical trial review process. For information on the benefits and risks of participating in HIV clinical trials, call CATIE toll-free at 1-800-263-1638.
